USA flag logo/image

An Official Website of the United States Government

TRANSFORMING GROWTH FACTOR-BETAS AS AGENTS FOR THE TREATMENTOF ARTHRITIS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7111
Program Year/Program:
1987 / SBIR
Agency Tracking Number:
7111
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Collagen Corp
2500 Faber Place Palo Alto, CA 94303
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1987
Title: TRANSFORMING GROWTH FACTOR-BETAS AS AGENTS FOR THE TREATMENTOF ARTHRITIS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

TWO HOMOLOGOUS PROTEINS, ISOLATED FROM DEMINERALIZED BOVINE BONE AND OPERATIONALLY REFERRED TO AS CARTILAGE-INDUCING FACTORS-A AND -B(CIF-A AND CIF-B), HAVE BEEN FOUND TO BE POTENT INHIBITORS OF LYMPHOCYTE FUNCTION AND TO HAVE ANTI-INFLAMMATORY ACTIVITY. THESE FACTORS HAVE THE SAME BIOLOGICAL ACTIVITIES AS THE HUMAN TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA). CIF-A AND TGF-BETA APPEAR TO BE THESAME MOLECULE (CIF-A/TGF-BETA), WHILE CIF-B HAS 63 PERCENT SEQUENCE HOMOLOGY. THE FOLLOWING OBSERVATIONS SUGGEST THESE ARE NATURALLY OCCURRING IMMUNOREGULATOR MOLECULES: (1) THESE FACTORS ARE ANTAGONISTS OF INTERLEUKIN-1 (THYMOCYTE PROLIFERATION ASSAY). (2) THESE FACTORS INHIBIT MITOGEN-INDUCED T-CELL AND B-CELL PROLIFERATION. (3) THESE FACTORS ARE POTENT INHIBITORS OF IGM AND IGG PRODUCTION BY PLASMA CELLS. (4) THESE FACTORS ARE ACTIVE AT <1.0NG/ML IN CULTURE. (5) CIF-A/TGF-BETA MRNA IS DETECTED IN MITOGEN-ACTIVATED LYMPHOCYTES AND IS SECRETED BY THESE CELLS. (6) EXOGENOUS FACTOR DOWN-REGULATES THE INTERLEUKIN-2 RECEPTOR. (7) THESEFACTORS EXHIBIT ANTI-INFLAMMATORY ACTIVITY IN VIVO. IN PHASE I OF THIS PROPOSAL, COLLAGEN CORPORATION WILL EVALUATE THE THERAPEUTIC USE OF THESE FACTORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES. POLYARTHRITIS WILL BE INDUCED IN RATS BY IMMUNIZING WITH TYPE II COLLAGEN. THE ARTHRITIS WILL BE TREATED BY INJECTING THESE IMMUNOSUPPRESSIVE FACTORS INTO THE INFLAMED JOINTS. THE EFFICACY OF TREATMENT WILL BE DETERMINED BY CLINICAL, IMMUNOLOGIC, HISTOPATHOLOGIC, AND RADIOGRAPHIC METHODS. IN PHASE II, RHEUMATOID ARTHRITIS PATIENTS WILL BE TREATED WITHTHERAPEUTICALLY EFFECTIVE AMOUNTS OF THESE FACTORS.

Principal Investigator:

Larry r ellingsworth phd
4158560200

Business Contact:

Small Business Information at Submission:

Collagen Corp
2500 Faber Place Palo Alto, CA 94303

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No